Instil Bio Inc. (TIL)
17.96
-1.40 (-7.23%)
At close: Mar 28, 2025, 3:59 PM
18.30
1.91%
After-hours: Mar 28, 2025, 07:55 PM EDT
-7.23% (1D)
| Bid | 17.88 |
| Market Cap | 117.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -74.14M |
| EPS (ttm) | -12.26 |
| PE Ratio (ttm) | -1.46 |
| Forward PE | -1.67 |
| Analyst | Buy |
| Ask | 18.64 |
| Volume | 43,166 |
| Avg. Volume (20D) | 91,948 |
| Open | 19.41 |
| Previous Close | 19.36 |
| Day's Range | 17.88 - 19.52 |
| 52-Week Range | 9.62 - 92.00 |
| Beta | 1.74 |
About TIL
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize f...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol TIL
Website https://instilbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $110, which is an increase of 512.47% from the latest price.
Stock Forecasts2 months ago
+14.84%
Instil Bio shares are trading higher after Jefferi...
Unlock content with
Pro Subscription
4 months ago
-5.51%
Instil Bio shares are trading higher after the company reported better-than-expected Q2 EPS results.
